Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Rang în acțiuni #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Preț acțiune
$5.47
Ultima sincronizare: 2026-08-14
Capitalizare de piață
$7.99M
Schimbare (1 zi)
6.21%
Schimbare (1 an)
7.47%
Țară
US
Tranzacționează CNS Pharmaceuticals, Inc. (CNSP)

Categorie

Venituri pentru CNS Pharmaceuticals, Inc. (CNSP)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale CNS Pharmaceuticals, Inc., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru CNS Pharmaceuticals, Inc. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE